PD-1 Developer Good Therapeutics Bought Out By Roche For $250M

Good Therapeutics has been scooped up by biopharma giant Roche for $250 million in cash as a key component of the latter’s ambitious plan for boosting its immuno-oncology segment. Seattle-based GT’s preclinical PD-1-regulated IL-2 program, meant to deliver effective IL-2 stimulation of T cells...